Sameer Jhavar

Dr. Sameer Jhavar


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in Asian Journal of Andrology
Verified
Journal Article
Open access
MGMichelle Guy
Michelle Guy
ZKZsofia Kote-Jarai
Zsofia Kote-Jarai
GGGraham G Giles
Graham G Giles
AOAli Amin Al Olama
Ali Amin Al Olama
SJSarah K. Jugurnauth
Sarah K. Jugurnauth
RERosalind Eeles
Rosalind Eeles
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.

Verified
Journal Article
Open access
PDF file
JLJared Luxton
Jared Luxton
MMMiles J. McKenna
Miles J. McKenna
ALAidan M. Lewis
Aidan M. Lewis
LTLynn E. Taylor
Lynn E. Taylor
SJSameer Jhavar
Sameer Jhavar
SBSusan Bailey
Susan Bailey
The ability to predict a cancer patient’s response to radiotherapy and risk of developing adverse late health effects would greatly improve personalized treatment regimens and individual outcomes. Telomeres represent a compelling biomarker of individual radiosensitivity and risk, as exposure can result in dysfunctional telomere pathologies that coincidentally overlap with many radiation-induced late effects, ranging from degenerative conditions like fibrosis and cardiovascular disease to proliferative pathologies like cancer. Here, telomere length was longitudinally assessed in a cohort of fifteen prostate cancer patients undergoing Intensity Modulated Radiation Therapy (IMRT) utilizing Telomere Fluorescence in situ Hybridization (Telo-FISH). To evaluate genome instability and enhance predictions for individual patient risk of secondary malignancy, chromosome aberrations were assessed utilizing directional Genomic Hybridization (dGH) for high-resolution inversion detection. We present the first implementation of individual telomere length data in a machine learning model, XGBoost, trained on pre-radiotherapy (baseline) and in vitro exposed (4 Gy γ-rays) telomere length measurements, to predict post radiotherapy telomeric outcomes, which together with chromosomal instability provide insight into individual radiosensitivity and risk for radiation-induced late effects.

1 April 2017 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
SJSameer Jhavar
Sameer Jhavar
GSGregory P. P Swanson
Gregory P. P Swanson
NDNiloyjyoti Deb
Niloyjyoti Deb
LLLake Littlejohn
Lake Littlejohn
JPJessica Pruszynski
Jessica Pruszynski
EBErin Bird
Erin Bird

16 November 2010 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
RERosalind Eeles
Rosalind Eeles
GKG. Knee
G. Knee
SJSameer Jhavar
Sameer Jhavar
JMJ. Mangion
J. Mangion
SES. Ebbs
S. Ebbs
JYJ. Yarnold
J. Yarnold

1 July 2020 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
GSGregory P. P Swanson
Gregory P. P Swanson
SJSameer Jhavar
Sameer Jhavar
KHKendall Hammonds
Kendall Hammonds
There is a lack of information on the radiosensitivity of lymphocyte subgroups to radiation alone. CD4+ and CD8+ lymphocytes respond similarly. CD 19+ dropped most precipitously, but recovered to levels similar to the other subgroups by 3 months. NK cells decline more modestly and recover more fully by 3 months.

24 July 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
GJGarrett L. Jensen
Garrett L. Jensen
NPNiloufar Pourfarrokh
Niloufar Pourfarrokh
MVMarcus Volz
Marcus Volz
LMLinden L. Morales
Linden L. Morales
KWKimberly Walker
Kimberly Walker
SJSameer Jhavar
Sameer Jhavar
With the growing interest in total neoadjuvant treatment for locally advanced rectal adenocarcinoma (LARC) there is an urgent unmet need to identify predictive markers of response to long-course neoadjuvant concurrent chemoradiotherapy (LCRT). O6-Methylguanine (O6-MG)-DNA-methyltransferase (MGMT) gene methylation has been associated in some malignancies with response to concurrent chemoradiotherapy. We attempted to find if pathologic response to LCRT was associated with MGMT promoter hypermethylation (MGMTh). Patients were identified with LARC, available pre-treatment biopsy specimens, and at least 1 year of follow-up who received LCRT followed by surgical resection within 6 months. Biopsies were tested for MGMTh using a Qiagen pyrosequencing kit (Catalog number 970061). The primary outcome of LCRT responsiveness was based on tumor regression grade (TRG), with grades of 0–1 considered to have excellent response and grades of 2–3 considered to be non-responders. Secondary outcomes included overall survival (OS) and recurrence free survival (RFS). Of 96 patients who met inclusion criteria, 76 had samples which produced reliable assay results. MGMTh corresponded with higher grade and age of the biopsy specimen. The percentage of responders to LCRT was higher amongst the MGMTh patients than the MGMTn patients (60.0% vs 27.5%, p value = 0.0061). MGMTh was not significantly associated with improved OS (2-year OS of 96.0% vs 98.0%, p = 0.8102) but there was a trend for improved RFS (2-year RFS of 87.6% vs 74.2%, p = 0.0903). Significantly greater tumor regression following LCRT was seen in MGMTh LARC. Methylation status may help identify good candidates for close observation without surgery following LCRT.